BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes
Rhea-AI Summary
BD (NYSE:BDX) announced on Dec 3, 2025 new three- and four-laser configurations of the BD FACSDiscover A8 Cell Analyzer, expanding access to spectral and real-time cell imaging for academia, pharma and biotech.
Key features include BD SpectralFX (analyzes up to 50+ cell characteristics), BD CellView Image for high-speed spatial/morphological imaging, optional free trials and later software upgrades, and compatibility with BD sorters and new near-infrared fluorochromes. Instruments are available to order with flexible financing options.
Positive
- Three- and four-laser configurations broaden accessibility across lab sizes
- BD SpectralFX enables analysis of up to 50+ characteristics per cell
- BD CellView offers real-time high-speed spatial and morphological imaging
- Option to start with a free trial of CellView and upgrade via software
- Compatibility with BD FACSDiscover cell sorters and new near-infrared fluorochromes
- Availability to order now with flexible financing options
Negative
- None.
Insights
BD expands market access for advanced spectral and imaging flow cytometry with lower-cost configurations and flexible upgrade paths.
BD released new three- and four-laser configurations of the BD FACSDiscover™ A8 Cell Analyzer on
The business mechanism is straightforward: broadened configuration options and optional software upgrades increase addressable customers by matching capability to budget and scale. The company also highlights integration with its sorter and reagent ecosystem and mentions flexible financing, which should ease procurement decisions for resource-constrained groups.
Dependencies and risks are explicit in the release: real uptake depends on actual lab adoption of spectral imaging workflows, effective field trials, and conversion from trials to purchases. Ease-of-use claims and automation will matter; user experience and compatibility with existing pipelines will determine replacement cycles.
Concrete items to watch in the near term are order volume and conversion rates from the free CellView™ trials, uptake of flexible financing offers, and any customer validation studies published over the next 6–12 months. These metrics will indicate whether the broader configurations materially expand market penetration.
Three- and Four-Laser BD FACSDiscover™ A8 Cell Analyzers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis
The new BD FACSDiscover™ A8 Cell Analyzers feature BD SpectralFX™ Technology, which allows scientists to analyze up to 50 or more characteristics of a single cell with optimal resolution and sensitivity, and BD CellView™ Image Technology, which enables high-speed imaging, revealing spatial and morphological insights – like the location of a protein within a single cell – that can be visually analyzed in real time. The three- and four-laser additions to the BD FACSDiscover™ A8 Cell Analyzer portfolio complement the five-laser instrument launched earlier this year, providing more scientists worldwide the opportunity to incorporate industry-leading capabilities in their labs. Both versions have the option to start with a free trial of CellView™ Image Technology and upgrade later via software – giving labs further flexibility.
"The BD FACSDiscover™ A8 Cell Analyzer has become our new standard, changing how our flow cytometry core operates," said Gert Van Isterdael, head of VIB Flow Core Ghent. "Once you experience the integration of spectral and imaging data, you don't want to go back. It opens a new dimension for our work, helping us see more, understand faster, and enable discoveries that simply weren't possible before. The BD FACSDiscover™ A8 Cell Analyzer is a game changer, and having more configurations will only make this leading technology more accessible to a wider range of labs."
All configurations of the BD FACSDiscover™ A8 Cell Analyzer feature high-throughput, walkaway automation that enables best-in-class cost-per-insight economics through real-time imaging. The intuitive software makes it easy to manage large datasets, and is designed for out-of-the-box standardization. The analyzers also pair seamlessly with the ecosystem of BD FACSDiscover™ Cell Sorters and BD Reagents. This includes the recently launched BD Horizon RealViolet™ 828 and RealBlue™ 824 fluorochromes, pioneering entries into the near-infrared spectrum that, when used with a cell analyzer, can unlock new discoveries through spectral flow cytometry.
"In today's complex research landscape, access to leading-edge technologies through flexibility and modularity is crucial, from basic to translational science," said Steve Conly, worldwide president of BD Biosciences. "Alongside the entire BD ecosystem of sorters, reagents, and informatics, the BD FACSDiscover™ A8 Cell Analyzer continues to be rapidly adopted by leading biopharmaceutical companies, and now with more entry points, organizations of all sizes can access the same technology."
BD FACSDiscover™ A8 Cell Analyzers are now available to order through local sales representatives. For researchers facing capital expenditure constraints, flexible financing options are now available. More information is available at bdbiosciences.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
| |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-new-cell-analyzer-configurations-to-bring-cutting-edge-capabilities-to-labs-of-all-sizes-302631129.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What did BD (BDX) announce on December 3, 2025 about the FACSDiscover A8?
How many cell characteristics can the BD FACSDiscover A8 analyze with BD SpectralFX?
Does the BD FACSDiscover A8 offer imaging and can labs trial it before buying (BDX)?
Are the new BD FACSDiscover A8 configurations compatible with BD reagents and sorters (BDX)?
When and how can labs order the BD FACSDiscover A8 (BDX)?
